We are live on ! Find out more
BOLD

Audentes Therapeutics, Inc
BOLD

Delisted

BOLD was delisted on the 14th of January, 2020.

Back to rankings

149 hedge funds and large institutions have $1.25B invested in Audentes Therapeutics, Inc in 2019 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 64 increasing their positions, 34 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

88% more repeat investments, than reductions

Existing positions increased: 64 | Existing positions reduced: 34

25% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 16

1% more funds holding

Funds holding: 147 → 149 (+2)

26% less capital invested

Capital invested by funds: $1.69B → $1.25B (-$438M)

49% less call options, than puts

Call options by funds: $1.1M | Put options by funds: $2.15M

63% less funds holding in top 10

Funds holding in top 10: 8 → 3 (-5)

Holders
149
Holders Change
+2
Holders Change %
+1.36%
% of All Funds
3.27%
Holding in Top 10
3
Holding in Top 10 Change
-5
Holding in Top 10 Change %
-62.5%
% of All Funds
0.07%
New
20
Increased
64
Reduced
34
Closed
16
Calls
$1.1M
Puts
$2.15M
Net Calls
-$1.05M
Net Calls Change
-$8.61M

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$21.7M
2
GPP
Great Point Partners
Connecticut
+$19.2M
3
BlackRock
BlackRock
New York
+$12.9M
4
Citadel Advisors
Citadel Advisors
Florida
+$11.8M
5
Millennium Management
Millennium Management
New York
+$8.71M

Top Sellers

Rank Fund Capital Flow
1
PHS
PFM Health Sciences
California
-$31.2M
2
GGHC
Gilder Gagnon Howe & Co
New York
-$24.1M
3
PAMU
Pictet Asset Management (UK)
United Kingdom
-$11M
4
Federated Hermes
Federated Hermes
Pennsylvania
-$10.5M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$8.52M
Name Holding Trade Value Shares
Change 		Change in
Stake
VVM
26
Versant Venture Management
California
$15.6M – – –
EAM
27
Eventide Asset Management
Massachusetts
$14M – – –
DM
28
Deerfield Management
New York
$13.9M – – –
Goldman Sachs
29
Goldman Sachs
New York
$13M +$4.31M +126,156 +37%
N
30
Nuveen
North Carolina
$11.7M +$6.39M +187,343 +82%
RSCM
31
Rock Springs Capital Management
Maryland
$11.5M – – –
T. Rowe Price Associates
32
T. Rowe Price Associates
Maryland
$11.1M -$7.93M -232,342 -37%
AG
33
Artal Group
Luxembourg
$9.83M – – –
FCMI
34
Foresite Capital Management III
California
$8.86M – – –
CS
35
Candriam SCA
Luxembourg
$8.45M – – –
UBS AM
36
UBS AM
Illinois
$8.02M +$203K +5,953 +2%
OM
37
Opaleye Management
Massachusetts
$8.01M +$171K +5,000 +2%
Charles Schwab
38
Charles Schwab
California
$7.69M +$1.66M +48,508 +22%
EP
39
Eversept Partners
New York
$7.13M +$3.21M +94,200 +59%
Point72 Asset Management
40
Point72 Asset Management
Connecticut
$6.77M +$597K +17,483 +8%
Franklin Resources
41
Franklin Resources
California
$6.62M +$97.8K +2,866 +1%
SIM
42
Spark Investment Management
New York
$6.41M -$1.1M -32,106 -12%
Morgan Stanley
43
Morgan Stanley
New York
$5.17M +$674K +19,744 +12%
Bank of New York Mellon
44
Bank of New York Mellon
New York
$5.01M +$413K +12,108 +7%
Macquarie Group
45
Macquarie Group
Australia
$4.32M – – –
JP Morgan Chase
46
JP Morgan Chase
New York
$3.65M +$205K +6,006 +5%
Deutsche Bank
47
Deutsche Bank
Germany
$3.61M +$554K +16,221 +14%
WM
48
WS Management
Florida
$3.33M -$446K -13,074 -10%
Squarepoint
49
Squarepoint
New York
$2.95M +$1.81M +53,053 +102%
UBS Group
50
UBS Group
Switzerland
$2.85M +$2.28M +66,938 +193%
1
2
3 4 5

BOLD Hedge Fund Activity: Q3 2019 in Review

149 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Audentes Therapeutics, Inc (BOLD) for Q3 2019, worth a combined $1.25B — down 26% from $1.69B a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new BOLD positions and 16 closed out — a net gain of 4 holders — while 64 added to existing stakes and 34 trimmed.

The largest buyer was Armistice Capital, opening a new position worth an estimated $21.7M. The largest seller was PFM Health Sciences, cutting an estimated $31.2M.

  • 149 institutional investors held Audentes Therapeutics, Inc (BOLD) as of Q3 2019, up from 147 in Q2 2019.
  • Funds reported $1.25B of Audentes Therapeutics, Inc stock for Q3 2019, down 26% quarter-over-quarter.
  • 20 funds opened new Audentes Therapeutics, Inc positions in Q3 2019 and 16 closed out, a net change of +4 holders.
  • The largest Audentes Therapeutics, Inc buyer in Q3 2019 was Armistice Capital, an estimated $21.7M added.
  • The largest Audentes Therapeutics, Inc seller in Q3 2019 was PFM Health Sciences, an estimated $31.2M sold.

Based on aggregated 13F filings for Q3 2019.